Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05812326

PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer

Exploratory Clinical Study of PD-1 Knockout Targeting MUC1 CAR-T Cells (AJMUC1) in the Treatment of MUC1-positive Advanced Breast Cancer

Sponsor: Guangzhou Anjie Biomedical Technology Co., Ltd.

Conditions Advanced Breast Cancer Breast Neoplasm Malignant Female

Interventions AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells

Updated 3 times since 2023 Last updated: Apr 11, 2023 Started: May 17, 2019 Primary completion: Nov 16, 2022 Completion: Nov 16, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Advanced Breast Cancer and Breast Neoplasm Malignant Female and is currently completed. Guangzhou Anjie Biomedical Technology Co., Ltd. leads this study, which shows 3 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2023 — Jul 2024 [monthly]

Completed PHASE1_PHASE2

First recorded

May 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guangzhou Anjie Biomedical Technology Co., Ltd.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Data source: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China